Track topics on Twitter Track topics that are important to you
Ruggell, Liechtenstein, 8 February 2011- Pantec Biosolutions AG, a privately-owned company developing innovative transdermal drug delivery products, announced today that a woman has successfully conceived after being implanted with a fertilized oocyte (egg cell). The oocyte donor was treated with the company’s FSH (follicle stimulating hormone) patch subsequent to skin microporation with Pantec’s proprietary P.L.E.A.S.E.® (Painless Laser Epidermal System) device.
The CEO of Pantec, Dr. Christof Boehler, announced this news during a scientific presentation at the 16th Annual Drug Delivery Partnerships 2011 conference in Miami, Florida, USA. The pregnancy is the first to occur from a previously announced study in which follicular maturation was achieved using P.L.E.A.S.E. microporation and the FSH (IVF002) patch. Following the oocyte donation, the fertilized egg was transferred to the recipient, who subsequently became pregnant. The trial team was led by principal investigator, Dr. Petr Uher and medical expert, Professor Herbert Zech. The presentation can be downloaded here.
“We are very pleased that our treatment has helped a patient conceive and we wish her the best during her pregnancy,” said Christof Boehler, CEO of Pantec Biosolutions. “This is an extremely important milestone; not only for our company, but also for all women undergoing IVF treatments- it is a big step towards making the tedious IVF procedure more comfortable for all those hoping to get pregnant.”
About Pantec Biosolutions and P.L.E.A.S.E.®
Pantec Biosolutions AG is a private drug delivery company specialised in using laser microporation technology to deliver large molecular weight drugs into the epidermis for local or systemic uptake. Its proprietary P.L.E.A.S.E.® (Painless Laser Epidermal System) platform enables efficient, needle-free and painless administration of biopharmaceutical drugs, in varying and individualised dosages, through partnered patch technology. The technology is currently in clinical trials for the delivery of IVF hormone therapy, a market with an estimated value of US$1.5 – 2 billion.
Pantec Biosolutions’ P.L.E.A.S.E.® platform is available both for the development of the Company’s own pipeline and for penetration into new markets through strategic partnerships. Pantec Biosolutions is based in Ruggell, Liechtenstein.
Dr. Christof Boehler
Pantec Biosolutions AG
t: +423 377 7800
Dr. Robert Mayer
Senior Account Manager
College Hill Life Sciences
t: +49 (0)89 52 38 80 30
Notes for editors:
Follicle-stimulating hormone (FSH) is a hormone found in humans and other animals. It is synthesized and secreted by gonadotropes of the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation, and reproductive processes of the body. FSH and Luteinizing hormone (LH) act synergistically in reproduction. FSH stimulates the growth and recruitment of immature ovarian follicles in the ovary.
Currently, FSH is self-administered by the patients for 10-12 days by daily subcutaneous or intramuscular injection stimulating follicle growth during an In Vitro Fertilisation (IVF) protocol. FSH is used in all major IVF procedures. The patch avoids these multiple injections thus improving ease of use and convenience.
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...